구강회복응용과학지 (Journal of Dental Rehabilitation and Applied Science)

  • 제29권2호
  • /
  • Pages.203-207
  • /
  • 2013
  • /
  • 2384-4353(pISSN)
  • /
  • 2384-4272(eISSN)
대한턱관절교합학회 (Korean Academy of Stomatognathic Function and Occlusion)
권호 표지
DOI QR코드

DOI QR Code

다학문적 임상 접근으로 치료된 건선 측두하악골관절염 증례

Psoriatic Temporomandibular Joint Arthritis Treated with Multidisciplinary Clinical Treatment : A case study

  • 조은애 (연세대학교 치과대학 구강내과학교실) ;
  • 안형준 (연세대학교 치과대학 구강내과학교실) ;
  • 박주현 (연세대학교 치과대학 구강내과학교실) ;
  • 김성택 (연세대학교 치과대학 구강내과학교실)
  • Cho, Eunae (Department of Orofacial Pain and Oral Medicine, College of Dentistry, Yonsei University) ;
  • Ahn, Hyung Joon (Department of Orofacial Pain and Oral Medicine, College of Dentistry, Yonsei University) ;
  • Park, Ju Hyun (Department of Orofacial Pain and Oral Medicine, College of Dentistry, Yonsei University) ;
  • Kim, Seong Taek (Department of Orofacial Pain and Oral Medicine, College of Dentistry, Yonsei University)
  • 투고 : 2013.05.02
  • 심사 : 2013.06.25
  • 발행 : 2013.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

건선 관절염은 건선과 관련된 만성 염증성 골관절염이다. 만성 건선 측두하악골관절염과 근막통증에 이환된 54세 남환이 메토트렉세이트와 근막통증 치료 프로토콜에 준한 치료를 적용했다. 3주후, 턱의 통증은 완화 되었으나 턱의 근육 촉진시 불편감은 잔존 하였다. 건선 측두하악골관절염의 경우, 종합적인 평가 및 다학문적 임상 치료가 필요하다.

Psoriatic arthritis is a chronic inflammatory form of arthritis that is associated with psoriasis. A 54-yr-old male with chronic psoriatic temporomandibular joint arthritis and myofascial pain was treated using methotrexate and a myofascial pain protocol. Jaw pain improved after 3 weeks, however, tenderness to palpation of muscles remained. Comprehensive evaluation and multidisciplinary clinical treatment is required for the treatment of patients with psoriatic temporomandibular joint arthritis.

키워드

참고문헌

  1. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. National Center for Health Statistics. Vital Health Statistics 1999;10(200):1-212.
  2. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3(1) 55-78. https://doi.org/10.1016/0049-0172(73)90009-7
  3. Sege-Peterson K, Winchester R. Psoriatic arthritis. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, et al, editors. Fitzpatrick's dermatology in general medicine. New York: McGraw-Hill; 1999522-33.
  4. Gladman DD. Psoriatic arthritis. Rheum Dis Clin North Am 1998;24:829-44. https://doi.org/10.1016/S0889-857X(05)70044-2
  5. Mease PJ, Goffe BS. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 2005;52: 1-19. https://doi.org/10.1016/j.jaad.2004.06.013
  6. Gottlieb AB. Etanercept for the treatment of psoriasis and psoriatic arthritis. Dermatol Ther. 2004;17:401-8. https://doi.org/10.1111/j.1396-0296.2004.04043.x
  7. Black RL, O'Brien WM, Vanscott EJ, Auerbach R, Eisen AZ, Bunium JJ. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA 1964;189:743-7.
  8. Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, et al. Randomized, doubleblind, plcebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376-81. https://doi.org/10.1002/art.1780270403
  9. Jones G, Crotty M, Brooks P. Interventions for treating psoriatic arthritis (Cochrane Review). Oxford: The Cochrane Library; 2001.
  10. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991;90:711-6. https://doi.org/10.1016/0002-9343(91)90667-M
  11. Bondeson J, Maini RN. Tumor necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE). Int J clin Pract 2001;55(3):211-6.
  12. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy and effect on disease progression. Arthritis Rheum 2004;50:2264-72. https://doi.org/10.1002/art.20335
  13. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000;356:385-90. https://doi.org/10.1016/S0140-6736(00)02530-7
  14. Antoni C, Manger B. infliximab for psoriasis and psoriatic arthritis. Clin Exp Rheumatol 2002;20: S122-5.
  15. Antoni C, Dechant C, Hanns-Martin Lorenz PD, et al. Open label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002;47:506-12. https://doi.org/10.1002/art.10671
  16. Galadari H, Fuchs B, Lebwohl M: Newly available treatments for psoriatic arthritis and their impact on skin psoriasis. Int J Dermatol 2003;42:231-7. https://doi.org/10.1046/j.1365-4362.2003.01449.x
  17. Zachariae H: Prevalence of joint disease in patients with psoriasis: Implications for therapy. Am J Clin Dermatol 2003;4:441-7. https://doi.org/10.2165/00128071-200304070-00001